Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study.
Etsuro MoriManabu IkedaEizo IsekiSadao KatayamaYasuhiro NagahamaMegumi OhdakeTakao TakasePublished in: Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society (2024)
The results support the observation that the efficacy of 10 mg donepezil in improving cognitive function is clinically meaningful in DLB patients. The evaluation of global clinical status might be affected by mild to moderate DLB patients enrolled in this study. No new safety concerns were detected.
Keyphrases
- placebo controlled
- double blind
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- study protocol
- peritoneal dialysis
- randomized controlled trial
- mild cognitive impairment
- patient reported outcomes
- squamous cell carcinoma
- cognitive impairment
- phase ii study
- locally advanced